Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H29NO3 |
| Molecular Weight | 319.4385 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1OC)[C@H]3C[C@H](O)[C@@H](CC(C)C)CN3CC2
InChI
InChIKey=WEQLWGNDNRARGE-UAGQMJEPSA-N
InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3/t14-,16+,17-/m0/s1
| Molecular Formula | C19H29NO3 |
| Molecular Weight | 319.4385 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:28:37 GMT 2025
by
admin
on
Tue Apr 01 16:28:37 GMT 2025
|
| Record UNII |
1JDAHLD17U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1JDAHLD17U
Created by
admin on Tue Apr 01 16:28:37 GMT 2025 , Edited by admin on Tue Apr 01 16:28:37 GMT 2025
|
PRIMARY | |||
|
862377-27-3
Created by
admin on Tue Apr 01 16:28:37 GMT 2025 , Edited by admin on Tue Apr 01 16:28:37 GMT 2025
|
PRIMARY | |||
|
11609432
Created by
admin on Tue Apr 01 16:28:37 GMT 2025 , Edited by admin on Tue Apr 01 16:28:37 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Cambridge Laboratories; Highest Development Phase: Discontinued for Huntington's disease; Most Recent Events: 28 Sep 2010 Biovail Corporation merged with Valeant Pharmaceuticals International forming Valeant Pharmaceuticals International, 22 May 2009 Phase-I clinical trials in Huntington's disease in United Kingdom (PO)
|
